Les recommandations européennes sur le télésuivi de la VNI

Maxime PATOUT

FHU UMANHYS
UMRS 1158 ***"Neurophysiologie Respiratoire Expérimentale et Clinique"***

maxime.patout@aphp.fr

Liens d'intérêts au cours des 4 dernières années

PSAD	Asten Santé, SOS Oxygène, Vitalaire, Bastide, Orkyn, Elivie, Isis, Air Liquide
Industrie pharm.	Chiesi, GSK, Jazz Pharmaceuticals, Novartis, Astra Zeneca, Sanofi, E. Lilly, Takeda
Matériel	Resmed, Philips Respironics, Loewenstein, Breas, Fisher & Paykel, Yuwell, Vestalis


Plan







Un nombre de patients croissants



Melloni B, Respiration 2018

Des ressources contraintes

Médicales et paramédicales

Economiques

Tele-monitoring of ventilator-dependent patients: a European Respiratory Society Statement

Un besoin d'actualisation

@ERSpublications
More research is needed to consider tele-monitoring an improvement in routine care of ventilator dependent patients http://ow.ly/16gM300hEhx

Ambrosino N, ERJ 2016

Mise en place

Suivi

Organisation


Chez les patients neuro-musculaires / restrictifs

In patients with NMD or RTD, should initiation of long-term HMV with telemedicine be used compared to initiation of HMV without the use of telemedicine?


Duiverman M L, ERJ 2025

Chez les patients neuro-musculaires / restrictifs

Forest plot for adherence



Forest plot for daytime PaCO2



Duiverman M L, ERJ 2025

Chez les patients neuro-musculaires / restrictifs

In patients with NMD or RTD we suggest the initiation of HMV with telemedicine *versus* initiation of HMV without telemedicine. *(Conditional recommendation for the intervention; very low certainty of evidence.)*


Duiverman M L, ERJ 2025


Chez les patients BPCO

In patients with COPD, should initiation of long-term HMV with telemedicine be used compared to initiation of HMV without the use of telemedicine?

Duiverman M L, ERJ 2025

Chez les patients BPCO





Duiverman M L, Thorax 2019

Chez les patients BPCO

In patients with COPD we suggest the initiation of HMV with telemedicine *versus* initiation of HMV without telemedicine. *(Conditional recommendation for the intervention; very low certainty of evidence.)*

Duiverman M L, ERJ 2025

Chez les patients SOH

In patients with OHS, should initiation of long-term HMV with telemedicine be used compared to initiation of HMV without the use of telemedicine?

Duiverman M L, ERJ 2025

Chez les patients SOH

In patients with OHS, due to the lack of evidence, we were unable to make any recommendation for or against the initiation of HMV with the use of telemedicine *versus* initiation of HMV without the use of telemedicine. *(No recommendation for or against the intervention; very low certainty of evidence.)*

Duiverman M L, ERJ 2025

Neuro-musculaire
On peut

BPCO
On peut

SOH
On ne sait pas


Dans le suivi au long terme

Should telemedicine be used to follow-up patients on long-term HMV compared to follow-up without telemedicine?


Duiverman M L, ERJ 2025

Dans le suivi au long terme

Forest plot for adherence



Forest plot for mean number of hospitalizations



Duiverman M L, ERJ 2025

Dans le suivi au long terme

In patients on long-term HMV, we suggest using either telemedicine-guided follow-up or treatment follow-up without telemedicine. *(Conditional recommendation for either the intervention or the comparison; very low certainty of evidence.)*

Duiverman M L, ERJ 2025

Au delà des données « machine »

Should extensive remote monitoring (*e.g.* remote gas exchange, sleep quality/apnoea, patient–ventilator synchrony) be used compared to limited remote monitoring only using ventilator data in patients on long-term HMV?

Duiverman M L, ERJ 2025

Au delà des données « machine »

Due to lack of studies addressing this issue, we were unable to make any recommendation. *(No recommendation.)*


Duiverman M L, ERJ 2025

Rôle potentiel de la télé-médecine

Mais peu dans le télésuivi


Niveau de preuve globalement très faible ou inexistant

Croissance du nombre de patients?




Malhotra A, NEJM 2024

Des ressources contraintes




Arnal JM, Respir Med Res 2026

Des ressources contraintes



Bianquis C, ERJOR 2025

Loi des rendements décroissants



Conclusion

Possible en mise en place

Peut être en suivi

Mais rapport bénéfice/coût indeterminé

Merci de votre attention

Maxime PATOUT

FHU UMANHYS
UMRS 1158 ***"Neurophysiologie Respiratoire Expérimentale et Clinique"***

maxime.patout@aphp.fr